France's ABIONYX Pharma H1 net loss widens as financial expenses rise

Abionyx Pharma SA

23/09/2026 20:45

Overview
France biopharma's H1 2026 revenue declined, driven solely by IRIS Pharma CRO activities
Net loss widened in H1 2026, mainly due to financial expenses from bond issuance
Company ended H1 2026 with €26.9 mln in cash after recent financing transaction

Outlook
Company expects IRIS Pharma revenue for 2026 to remain broadly stable vs 2025
ABIONYX Pharma remains focused on GMP production for sepsis and LCAT deficiency
Company preparing for next regulatory steps for Phase 2b sepsis trial

Result Drivers
NO CORE REVENUE - Co's main business in sepsis and LCAT deficiency did not generate revenue in H1 2026; revenue came solely from IRIS Pharma's CRO activities
HIGHER FINANCIAL EXPENSES - Net loss widened due to financial expenses from Fenja straight bonds issuance and fair-value measurement

Company press release: ID:nBw3vdlDTa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Loss
 
EUR 4.81 mln
 
H1 EBIT
 
-EUR 2.27 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Abionyx Pharma SA is €10.00, about 440.5% above its September 23 closing price of €1.85

Reuters Recommended Reads
Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs
Sept 22 - European drugmakers call for faster trials, more spending to compete with US, China
Sept 22 - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)